Table II.
Effect of DEP Exposure on M.tb-induced Host Gene Expression.
| Functional group | Genes | DEP stimulation condition |
Fold Change relative to M.tb |
|---|---|---|---|
| Cytokines and Cytokine Receptors | IL5 | Pre | ↓ 9 |
| IL6 | Pre | ↓ 8.9–9.5 | |
| IFNG | Simultaneous and Pre | ↓ 5 – 5.4 and 6.1 – 7.3 | |
| IFNA1 | Pre | ↓ 6.4 | |
| IFNB1 | Pre | ↓ 4.7 | |
| IL1A | Pre | ↓ 4 | |
| CSF3 | Pre | ↓ 3.5 | |
| IL18 | Pre | ↑ 3.2 | |
| CSF2 | Simultaneous | ↑ 2.4–2.7 | |
| IL7 | Pre | ↓ 2.2 | |
| IL2RA | Pre | ↓ 2.3 | |
| IL18R1 | Pre | ↓ 2.2 | |
| IL1R1 | Simultaneous | ↑ 2.2 | |
| IL13RA | Pre | ↑ 2.1 | |
| Chemokines and receptors | CXCL10 | Simultaneous and Pre | ↓ 3.48 and 5.3 |
| CXCR3 | Pre | ↓ 3 | |
| CCL5 | Pre | ↓ 2.4 | |
| CCL7 | Simultaneous | ↓ 2.3 | |
| CCR4 | Pre | ↓ 2.1 | |
| Transcription factors and inhibitors | NFKB1A | Pre | ↓ 9.6 |
| SOCS1 | Pre | ↓ 2.6 | |
| FOS | Pre | ↑ 2.6 | |
| GATA3 | Pre | ↓ 2 | |
| CEBPB | Pre | ↑ 2 | |
| Toll-like receptors | TLR7 | Pre | ↓ 4.7 |
| TLA4 | Simultaneous and pre | ↓ 2.3 and 3.8 | |
| TLR3 | Pre | ↓ 3.1 | |
| TLR10 | Pre | ↓ 2.4 | |
| TLR5 | Simultaneous | ↑ 2.1 | |
| Costimulatory molecules, T cell activation | CD86 | Pre | ↑ 2.8–3.5 |
| CD80 | Pre | ↓ 2.4–2.7 | |
| LAG3 | Pre | ↓ 2.7 | |
| CTLA4 | Pre | ↓ 2.6 | |
| ICOS | Pre | ↓ 2.3 | |
| TNFSF4 | Pre | ↓ 2.2 | |
| IFN-responsive effector | EIF2AK2 | Pre | ↓ 5.6 |
| SPP1 | Pre | ↑ 2.1 | |
| Others | FASLG | Pre | ↓ 3.0 |
| PTGS2 | Pre | ↓ 3.6 | |
| IGSF6 | Pre | ↑ 3.9 | |
The mRNA levels of PBMC stimulated simultaneously with M.tb and DEP (simultaneous) and with M.tb following DEP pre-stimulation (Pre) were compared with that of PBMC stimulated with M.tb alone. mRNA expression levels that were increased or decreased by ≥ 2-fold (p ≤ 0.01) relative to the mRNA expression levels of PBMC stimulated with M.tb alone are shown. Abbreviations shown: IL5 interleukin 5, IL6 interleukin 6, IFNG interferon gamma, IFNA1 interferon alpha 1, IFNB1 interferon beta 1, fibroblast, IL1A interleukin 1 alpha, CSF3 colony stimulating factor 3 (granulocyte), IL18 interleukin 18 (interferon-gamma-inducing factor), CSF2 colony stimulating factor 2 (granulocyte-macrophage), IL7 interleukin 7, IL2RA interleukin 2 receptor alpha, IL18RA interleukin 18 receptor 1, IL1R1 interleukin 1 receptor, type I, IL13RA1 interleukin 13 receptor alpha 1, CXCL10 chemokine (C-X-C motif) ligand 10, CXCR3 chemokine (C-X-C motif) receptor 3, CCL5 chemokine (C-C motif) ligand 5, CCL7 chemokine (C-C motif) ligand 7, CCR4 chemokine (C-C motif) receptor 4, NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha, SOCS1 suppressor of cytokine signaling 1, FOS V-fos FBJ murine osteosarcoma viral oncogene homolog, GATA3 trans-acting T-cell-specific transcription factor, CEBPB CCAAT/enhancer binding protein (C/EBP) beta, TLR7 toll-like receptor 7, TLR4 toll-like receptor 4, TLR3 toll-like receptor 3, TLR10 toll-like receptor 10, TLR5 toll-like receptor 5, CD86 CD86 molecule, CD80 CD80 molecule, LAG3 (lymphocyte-activation gene 3), CTLA4 cytotoxic T-lymphocyte-associated protein 4, ICOS inducible T-cell co-stimulator, TNFSF4 (tumor necrosis factor (ligand) superfamily member 4), EIF2AK2 (eukaryotic translation initiation factor 2-alpha kinase 2), SPP1 secreted phosphoprotein 1 (osteopontin, bone sialoprotein 1, early T-lymphocyte activation), FASLG Fas ligand, PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), IGSF6 immunoglobulin superfamily member.